Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous beta-lactam antibiotics in hospitalized children with infections
ACTRN12626000732381Phase 2Recruiting
- Sponsor
- Child and Adolescent Health Service
- Start
- Aug 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ceftriaxone, cefazolin and meropenem in Infection (2 arms), sponsored by Child and Adolescent Health Service. Primary endpoint: Absolute bioavailability of subcutaneous compared with intravenous administration. Started Aug 2026; status: recruiting.
02
Drugs
ceftriaxonecefazolinmeropenem
03
Conditions
Infection
Beyond the preview
Go deeper on ACTRN12626000732381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000732381.